Cargando…
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
BACKGROUND: Adoptive immunotherapy using T cells expressing chimeric antigen receptors (CARs) targeting CD19 has produced remarkable clinical outcomes. However, much of the mechanisms of action, such as the development of memory responses and sources of immune cytokines, remain elusive largely due t...
Autores principales: | Jin, Chun-Hui, Xia, Jinxing, Rafiq, Sarwish, Huang, Xin, Hu, Zheng, Zhou, Xianzheng, Brentjens, Renier J., Yang, Yong-Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354733/ https://www.ncbi.nlm.nih.gov/pubmed/30579863 http://dx.doi.org/10.1016/j.ebiom.2018.12.013 |
Ejemplares similares
-
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019) -
Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022) -
How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012) -
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018) -
CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)